Patient Guide: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 342 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06065748
Status: 🟢 Enrolling Now
Condition: Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Phase: PHASE3

Where You Can Participate

This study is available at 342 locations across the country.

Top locations include:
  • • Daphne, Alabama
  • • Auburn, California
  • • Glendale, California
  • • And 339 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) - Join Clinical Trial NCTNCT06065748

How to Join This Clinical Trial - NCTNCT06065748

Learn how to participate in this PHASE3 trial studying an investigational therapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Treatment Being Tested
Investigational treatment
Study Phase
PHASE3 - Large-scale efficacy study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06065748 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 342 locations. Find a study site near you:

Clinical Research Site

Daphne, Alabama 36526 - United States

Status: RECRUITING

Clinical Research Site

Auburn, California 95602 - United States

Status: RECRUITING

Clinical Research Site

Glendale, California 91260 - United States

Status: RECRUITING

Clinical Research Site

Greenbrae, California 94904 - United States

Status: RECRUITING

Clinical Research Site

Harbor City, California 90710 - United States

Status: RECRUITING

Clinical Research Site

Los Angeles, California 90033 - United States

Status: RECRUITING

Clinical Research Site

Newport Beach, California 92663 - United States

Status: RECRUITING

Clinical Research Site

Roseville, California 95661 - United States

Status: RECRUITING

Clinical Research Site

Sacramento, California 95816 - United States

Status: RECRUITING

Clinical Research Site

Torrance, California 90502 - United States

Status: RECRUITING

And 332 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE3 clinical trial for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships